Your browser doesn't support javascript.
loading
Intravenous BCG vaccination reduces SARS-CoV-2 severity and promotes extensive reprogramming of lung immune cells.
Singh, Alok K; Wang, Rulin; Lombardo, Kara A; Praharaj, Monali; Bullen, C Korin; Um, Peter; Gupta, Manish; Srikrishna, Geetha; Davis, Stephanie; Komm, Oliver; Illei, Peter B; Ordonez, Alvaro A; Bahr, Melissa; Huang, Joy; Gupta, Anuj; Psoter, Kevin J; Creisher, Patrick S; Li, Maggie; Pekosz, Andrew; Klein, Sabra L; Jain, Sanjay K; Bivalacqua, Trinity J; Yegnasubramanian, Srinivasan; Bishai, William R.
Afiliação
  • Singh AK; Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, MD, USA.
  • Wang R; Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Lombardo KA; Johns Hopkins University, School of Medicine, Department of Urology, Baltimore, MD, USA.
  • Praharaj M; Bloomberg∼Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA.
  • Bullen CK; Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, MD, USA.
  • Um P; Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, MD, USA.
  • Gupta M; Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, MD, USA.
  • Srikrishna G; Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, MD, USA.
  • Davis S; Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, MD, USA.
  • Komm O; Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, MD, USA.
  • Illei PB; Johns Hopkins University, School of Medicine, Department of Pathology, Baltimore, MD, USA.
  • Ordonez AA; Johns Hopkins University, School of Medicine, Department of Pediatrics, Division of Infectious Diseases, Baltimore, MD, USA.
  • Bahr M; Johns Hopkins University, School of Medicine, Department of Pediatrics, Division of Infectious Diseases, Baltimore, MD, USA.
  • Huang J; Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, MD, USA.
  • Gupta A; Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Psoter KJ; Johns Hopkins University, School of Medicine, Department of Pediatrics, Division of General Pediatrics, Baltimore, MD, USA.
  • Creisher PS; Johns Hopkins University, Bloomberg School of Public Health, The W. Harry Feinstone Department of Molecular Microbiology and Immunology, Baltimore, MD, USA.
  • Li M; Johns Hopkins University, Bloomberg School of Public Health, The W. Harry Feinstone Department of Molecular Microbiology and Immunology, Baltimore, MD, USA.
  • Pekosz A; Johns Hopkins University, Bloomberg School of Public Health, The W. Harry Feinstone Department of Molecular Microbiology and Immunology, Baltimore, MD, USA.
  • Klein SL; Johns Hopkins University, Bloomberg School of Public Health, The W. Harry Feinstone Department of Molecular Microbiology and Immunology, Baltimore, MD, USA.
  • Jain SK; Johns Hopkins University, School of Medicine, Department of Pediatrics, Division of Infectious Diseases, Baltimore, MD, USA.
  • Bivalacqua TJ; Perelman School of Medicine at the University of Pennsylvania, Division of Urology, Department of Surgery, Philadelphia, PA, USA.
  • Yegnasubramanian S; Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Bishai WR; Johns Hopkins University, School of Medicine, Department of Medicine, Center for Tuberculosis Research, Baltimore, MD, USA.
iScience ; 26(10): 107733, 2023 Oct 20.
Article em En | MEDLINE | ID: mdl-37674985
ABSTRACT
Bacillus Calmette-Guérin (BCG) confers heterologous immune protection against viral infections and has been proposed as vaccine against SARS-CoV-2 (SCV2). Here, we tested intravenous BCG vaccination against COVID-19 using the golden Syrian hamster model. BCG vaccination conferred a modest reduction on lung SCV2 viral load, bronchopneumonia scores, and weight loss, accompanied by a reversal of SCV2-mediated T cell lymphopenia, and reduced lung granulocytes. BCG uniquely recruited immunoglobulin-producing plasma cells to the lung suggesting accelerated local antibody production. BCG vaccination also recruited elevated levels of Th1, Th17, Treg, CTLs, and Tmem cells, with a transcriptional shift away from exhaustion markers and toward antigen presentation and repair. Similarly, BCG enhanced recruitment of alveolar macrophages and reduced key interstitial macrophage subsets, that show reduced IFN-associated gene expression. Our observations indicate that BCG vaccination protects against SCV2 immunopathology by promoting early lung immunoglobulin production and immunotolerizing transcriptional patterns among key myeloid and lymphoid populations.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article